KLOW - BPC-157 | TB-500 | GHK-Cu | KPV Peptide

KLOW is a four-peptide research blend formulated for investigators studying how regenerative, matrix-signaling, and immune-modulatory pathways interact in preclinical models. The blend combines BPC-157 (Body Protection Compound-157, 15 aa, MW 1,419.53 g/mol), TB-500 (thymosin β-4, 43 aa, MW 4,963.44 g/mol), GHK-Cu (copper-bound tripeptide, ~403.9 g/mol as Cu²⁺ complex), and KPV (Lys-Pro-Val, α-MSH 11-13 fragment, MW 342.44 g/mol) in a single lyophilized vial.

The scientific rationale reflects four distinct but convergent pathways. BPC-157 has been investigated for FAK–paxillin-mediated cell migration, nitric oxide homeostasis, and VEGF-driven angiogenesis (BPC-157 mechanism of action). TB-500 is studied for G-actin sequestration and endothelial migration (TB-500 research applications). GHK-Cu research focuses on copper-dependent matrix metalloproteinase modulation, TGF-β signaling, and antioxidant gene expression (GHK-Cu mechanism of action). KPV is characterized in NF-κB and melanocortin-1 receptor (MC1R) studies relevant to colitis and dermal inflammation models.

KLOW extends the three-peptide GLOW blend by adding KPV, introducing explicit anti-inflammatory and immunomodulatory chemistry to the tissue-repair stack. Researchers comparing KLOW, GLOW, and WOLVERINE can isolate the incremental contribution of copper-peptide and α-MSH chemistry in the same model system. A deeper narrative on the blend rationale is available in the companion article KLOW blend: BPC-157 + TB-500 + GHK-Cu + KPV.

Each peptide in the KLOW blend has been independently characterized in published research. The mechanistic rationale for combining them in a single preparation is that their signaling pathways are largely non-overlapping but converge on wound-microenvironment biology.

BPC-157 — FAK-paxillin and nitric oxide. BPC-157 has been shown to increase phosphorylation of focal adhesion kinase (FAK) and paxillin without altering total protein levels, a pattern consistent with activation rather than induction. In parallel, published models describe apparent modulation of nitric oxide synthase (NOS) activity and upregulation of VEGF in granulation tissue. See What is BPC-157? and BPC-157 mechanism of action for the full pathway map.

TB-500 — actin remodeling and endothelial migration. TB-500 (full-length thymosin β-4 in most research preparations) contains the N-terminal actin-binding motif that sequesters G-actin and supports cytoskeletal remodeling during endothelial cell migration. Studies by Malinda et al. (1999) and Goldstein et al. (2005/2012) report effects on angiogenesis, corneal repair, and cardiac progenitor mobilization. See What is TB-500? and the comparison TB-500 vs BPC-157.

GHK-Cu — copper-dependent matrix signaling. The GHK tripeptide has high affinity for Cu²⁺ and the copper complex is the research-relevant species. Pickart and colleagues describe modulation of ~4,000 genes including upregulation of antioxidants (SOD2, MT1X), DNA repair factors, and anti-inflammatory mediators, alongside TGF-β and metalloproteinase effects on the dermal extracellular matrix. See GHK-Cu mechanism of action and GHK-Cu molecular structure.

KPV — NF-κB and melanocortin signaling. KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH. Published research reports suppression of NF-κB nuclear translocation and downregulation of TNF-α, IL-6, and IL-1β in intestinal epithelial and immune-cell models. Dalmasso et al. (2008) used orally delivered KPV-loaded nanoparticles in DSS- and TNBS-induced colitis models and reported reductions in inflammation scores at microgram doses. This provides the explicit anti-inflammatory dimension absent from the three-peptide GLOW preparation.

Why a blend. The four pathways (FAK-paxillin migration, actin remodeling, copper-matrix signaling, NF-κB suppression) sit at different layers of the tissue response — initial cell migration, cytoskeletal reorganization, matrix deposition, and inflammatory tone. Investigators studying compound-interaction or pathway-complementarity use KLOW to expose a preparation to all four layers simultaneously rather than running four parallel reconstitutions.

The KLOW vial is a co-lyophilized preparation of four peptides. Each component has its own molecular identity; the table below summarizes the verified parameters for the individual peptides, which researchers use when calculating per-component concentrations after reconstitution.

BPC-157 is notable for its stability in human gastric juice (stable at pH 1.0 for >24 hours in published work), which is not representative of the other three components. The GHK-Cu fraction contributes the faint blue coloration characteristic of copper-peptide complexes.

Follow standard aseptic technique for the laboratory environment. Because KLOW is a co-lyophilized four-peptide blend, the reconstitution protocol treats the vial as a single preparation rather than four independent solutions.

1. Allow the vial to reach room temperature (15–25 °C) before opening to minimize condensation on the lyophilized cake.
2. Reconstitute with bacteriostatic water for injection (BWFI, 0.9% benzyl alcohol) or sterile WFI depending on protocol requirements. A typical working concentration is achieved by adding 2–3 mL of solvent to the standard vial.
3. Add solvent slowly down the inner wall of the vial — do not direct the stream at the lyophilized cake.
4. Swirl gently to dissolve. Do not shake or vortex. TB-500 contains a methionine residue susceptible to oxidation, and agitation accelerates peptide degradation.
5. Allow the vial to sit undisturbed for 30–60 seconds; the GHK-Cu fraction may produce a faint blue tint as it solubilizes.
6. Inspect visually. The solution should be clear to faintly blue. Cloudy or particulate-containing solutions should not be used.

For per-component concentration calculations, researchers typically use the published mass fraction listed on the COA; the four components are present in a defined ratio established at the lyophilization step. The peptide reconstitution calculator can be used to convert total-vial mass to working concentration when the per-component mass is known.

Compound-specific handling notes: the methionine in TB-500 should be protected from light and oxidative conditions; the copper ion in GHK-Cu is sensitive to strong chelators (EDTA, DTPA) and acidic conditions below pH 4; BPC-157 is exceptionally stable across a wide pH range and is typically the most robust component of the blend.

The lyophilized KLOW vial is stable when stored per the conditions below. Stability parameters reflect the least-stable component of the blend (TB-500, due to methionine oxidation susceptibility), so the stored preparation should be managed conservatively.

• Lyophilized, long-term: −20 °C, protected from light, in the original sealed vial. Stable for 24+ months under these conditions.
• Lyophilized, short-term: 2–8 °C for up to 90 days.
• Transit / room temperature: acceptable for <30 days for the lyophilized form; freeze upon receipt.
• Reconstituted, refrigerated: 2–8 °C, used within 14–21 days. BWFI-reconstituted solutions are typically the longest-stable research-use preparation.
• Reconstituted, frozen: avoid repeated freeze-thaw cycles. If freezing is required, aliquot in single-use volumes.

Compound-specific stability notes that apply to the KLOW preparation:

• TB-500: methionine residue susceptible to oxidation — protect from oxygen exposure and light. See TB-500 handling and storage guide.
• GHK-Cu: copper ion sensitive to acidic conditions below pH 4 and to strong chelators — avoid buffers that contain EDTA, DTPA, or citrate above trace concentrations. See GHK-Cu handling and storage.
• BPC-157: exceptionally stable — published work reports stability at pH 1.0 for >24 hours. See BPC-157 stability and storage.
• KPV: short tripeptide, generally stable in lyophilized form; avoid prolonged exposure to strongly basic conditions.